42 results about "Streptococcus uberis" patented technology

The present invention provides peptides and analogs and derivatives thereof having antimicrobial activity at least against Streptococcus uberis for the treatment of a range of infectious disease mastitis, otitis externa, clostridial intestinal disease and respiratory disease.

The invention provides compositions comprising one or more isolated LDH-deficient mutans streptococcus strains and one or more isolated S. oralis strains and / or one or more isolated S. uberis strains. Compositions of the invention are useful to maintain oral health, by for example treating and / or preventing one or more symptoms of dental caries, periodontitis and / or other oral cavity diseases or wounds.

The invention discloses an LAMP primer combination for detecting 8 environmental pathogens of dairy cow mastitis and application thereof. The primer combination provided by the invention is composed of 48 primers shown in sequence 1 to sequence 48. The primer combination provided by the invention can be used for detecting whether a to-be-detected bacterium is Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus dysgalactiae, Streptococcus uberis, Salmonella typhimurium, Proteus mirabilis or Candida albicans, and can be used for detecting whether a to-be-detected sample contains Escherichia coli and / or Klebsiella pneumonia and / or Pseudomonas aeruginosa and / or Streptococcus dysgalactiae and / or Streptococcus uberis and / or Salmonella typhimurium and / or Proteus mirabilis and / or Candida albicans. The primer combination provided by the invention is used for identifying and detecting the 8 environmental pathogens of dairy cow mastitis, has high specificity and high sensitivity, and can realize simple, rapid and accurate detection, thus having great popularization value.

The invention discloses rare earth metal complexes using orbifloxacin as a ligand, a method for synthesizing the same and application thereof. In the tests of the inhibiting effect of the complexes on bacteria such as salmonella pullorum, swine streptococcosis and bovine streptococcus uberis, the results show that the complexes have quite high bacteriostatic activity, wherein all of Er(III), Sm(III) and Eu(III) complexes of the orbifloxacin have certain bacteriostatic activity on the swine streptococcosis which cannot be inhibited by orbifloxacin and doxycycline. Mouse acute toxicity tests show that the complexes have low in-vivo toxicity to mice and are highly tolerable to mice. The toxicity of various complexes meets the acute oral toxicity ungraded standards of European Community and the PRC food security assessment grade-two (actually non-toxic) standard, wherein the neodymium complex of the orbifloxacin has the lowest toxicity.

A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the invention.

This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi, and various Enterococci and Staphylococcus aureus. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in E. coli stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.

The invention provides a GIT fusion protein used for preventing dairy cow mastitis. The GIT fusion protein has an amino acid sequence as represented by SEQ ID No. 1 or an amino acid sequence which is formed after substitution, deletion or addition of one or a plurality of amino acids of the sequence represented by SEQ ID No. 1 and has same functions as the sequence represented by SEQ ID No. 1 does. The invention also provides the nucleotide sequence of the protein and a preparation method and application for the same. The protein has good immunogenicity, can effectively prevent infection caused by Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus agalactiae and Streptococcus uberis, has a wide immune range and can be used for preventing dairy cow mastitis; moreover, while immunoprotection effects of the GIT fusion protein provided in the invention is guaranteed, preparation process and immune procedures in actual production are simplified, the length of the peptide chain of the fusion protein is shortened, expression of the fusion protein is enhanced, and the GIT fusion protein has an important value in development and application of novel vaccines.

The invention discloses streptococcus and a dairy cow mastitis vaccine obtained by inactivating the streptococcus. The active components of the dairy cow mastitis vaccine are an inactivated strain SAWR-6 (streptococcus agalactiae-6), an inactivated strain SDTR-9 (streptococcus dysgalactiae-9) and an inactivated strain SURF-5 (streptococcus uberis-5). The invention also provides a dairy cow mastitis vaccine, of which the active components are inactivated strains and capsular polysaccharides, wherein the inactivated strains are an inactivated strain SAWR-6, an inactivated strain SDTR-9 and an inactivated strain SURF-5; the capsular polysaccharides are strain SAWR-6 capsular polysaccharide, strain SDTR-9 capsular polysaccharide and strain SURF-5 capsular polysaccharide. The vaccine disclosed by the invention has the advantages of high efficiency, universality, safety, stability, various preparations and the like, a powerful guarantee is provided to safe, effective and comprehensive and effective prevention of streptococcus infected dairy cow mastitis, and the vaccine is a new milestone for the development of dairy cow mastitis vaccine.

The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.

The invention discloses a method for quickly detecting pathogenic bacteria in cow endometritis. The method comprises the following steps of (1) extracting DNA of 6 common pathogenic bacteria which arecultured over night, in womb secretion by a reagent kit method; (2) in a reaction system containing the DNA of the bacteria, adding a PCR primer system which can detect the specificity sequence of the 6 kinds of bacteria at the same time, and performing amplification; and (3) preparing 2% of agarose gel, performing gelatin electrophoresis, wherein the voltage is 120 V and the time is 45 min, andthen performing electrophoresis ultraviolet imaging. Based on a multiple polymerase chain reaction technique, the method disclosed by the invention can realize detection of 6 kinds of the bacteria, including E.coli, S.aureus, T.pyogenes, S.uberis, P.mirabilis and P.aeruginosa. Compared with sequencing, techniques of substance PCR and the like are simpler and more convenient to operate, lower in cost, higher in sensitivity and specificity. The detection and identification period for clinical bacterium detection are selected.

The invention provides a primer set and kit for detecting the serotype of streptococcus parauberis, and belongs to the technical field of fish disease detection. The primer set comprises a Parauberis1primer pair and a Parauberis2 primer pair. The primer set can accurately, specifically, rapidly and sensitively distinguish the serotype of the fish-derived streptococcus parauberis.

The invention discloses a method for producing glutathione by using bifunctional glutathione synthetase contained in actinobacillus pleuropneumonia, actinobacillus succinogenes, bacillus cereus, streptococcus sanguis, streptococcus gordonii, streptococcus uberis and streptococcus thermophilus. The method comprises heterologous expression by using the seven microbes or enzymes of the microbes in other microbes. The glutathione synthesized by using the method has the structure of natural glutathione, and has high response rate and high output and yield of the glutathione.

The invention discloses a lincomycin hydrochloride oil solution and a preparation method and application thereof, and belongs to the field of medicine and pharmacy. The lincomycin hydrochloride oil solution overcomes the problem of the easy settlement of a mixed suspend lincomycin hydrochloride oil preparation. The lincomycin hydrochloride oil solution is simple in preparation process only needing common physical mixing without grinding process. The lincomycin hydrochloride oil solution is free of visible insolubles under a microscope, and can be sterilized through a 0.22 mum millipore filter film. The lincomycin hydrochloride oil solution product has good liquidity, and may not be hung on the wall, the appearance is single-phase, transparent and clear, clarity detection is acceptable, and after repeated freezing and thawing, preparation stratification and drug settlement phenomenon may not occur. The lincomycin hydrochloride oil solution has the advantages of simple process, stable quality and great application prospect. The lincomycin hydrochloride oil solution product is used for treatment of mastitis of lactating cows infected with staphylococcus aureus, streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis escherichia coli and fungus and the like.

This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus equi, and various Enterococci and Staphylococcus aureus. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed in E. coli stain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.

The present invention discloses specific LAMP primers, kit and method for detecting streptococcus uberis. The kit comprises the six LAMP primers including outer primers F3 and B3, inner primers FIP and BIP and loop primers LB and LF, and the six primers aim at conserved sequence design of a streptococcus uberis KX389960. 1 gene; and a nucleotide sequence of FIP is as shown in SEQ ID NO.1, a nucleotide sequence of BIP is as shown in SEQ ID NO.2, a nucleotide sequence of F3 is as shown in SEQ ID NO.3, a nucleotide sequence of B3 is as shown in SEQ ID NO.4, a nucleotide sequence of LB is as shownin SEQ ID NO.5, and a nucleotide sequence of LF is as shown in SEQ ID NO.6. The kit solves the problems that an existing breast streptococcus detection technology has the long period and the high detection cost and cannot be applied to on-site rapid detection.

The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

The invention provides a milk cow Streptococcus uberis subunit vaccine GapC protein, and a preparation method and application thereof. The amino acid sequence of the GapC protein is disclosed as SEQ ID NO.1. Since the subunit vaccine prepared from bovine-derived streptococcus GapC protein has a cross protective function on three common milk cow Streptococci uberis, compared with other vaccines, the milk cow Streptococcus uberis subunit vaccine GapC protein provided by the invention has a more broad-spectrum protective function, and can be used as a candidate antigen of a milk cow uberis subunit vaccine.

The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

The present invention relates to an extract of Streptococcus uberis as an immunogenic agent. It also relates to a process for obtaining said agent which comprises incubating a biofilm-producing S. uberis strain to obtain a biofilm and thermally treating the biofilm obtained. It relates also to a pharmaceutical composition comprising teichoic acids, preferably lipoteichoic acids, for use in the prevention and / or treatment of mastitis and / or infections caused by Streptococcus sp. or by biofilm-producing bacteria. The present invention also relates to a vaccine which comprises said immunogenic agent and to said vaccine and immunogenic agent for use in the prevention and / or treatment of infections caused by Streptococcus sp., especially in the prevention and / or treatment of mastitis caused by S. uberis. It also relates to a vaccination kit which comprises said agent or vaccine.

An deactivated multi-bacterium vaccine for preventing the mastitis of milk cow is composed of Staphylococcus aureus, agalactic streptococcus, milk-stopping streptococcus, breast streptococcus, colibacillus and aluminum hydroxide gel. Its preparing process includes such steps as choosing the pathogenic bacterial strain of said mastitis, preparing seed liquid and reproduction liquid, purity checking, deactivating, preparing vaccine, and discriminating.

The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.

The invention provides a kit for detecting dairy cow mastitis pathogenic bacteria. Comprising a primer for amplifying staphylococcus aureus, a primer for amplifying staphylococcus epidermidis, a primer for amplifying streptococcus agalactiae, a primer for amplifying streptococcus dysgalactiae, a primer for amplifying streptococcus uberis, a primer for amplifying enterococcus, a primer for amplifying pseudomonas aeruginosa, a primer for amplifying enterobacter and a primer for amplifying escherichia coli. A primer for amplifying Klebsiella pneumoniae, a primer for amplifying listeria monocytogenes and a primer for amplifying mycoplasma bovis. The invention also provides a method for detecting cow mastitis by adopting the kit. The method has the advantages of being convenient to operate, free of special instruments and low in cost, not only can provide powerful help for accurate diagnosis and treatment of a farm, but also has the advantages of being high in detection efficiency and low in cost, is very suitable for basic-level use and has the condition of large-scale application and popularization.

The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.

The invention discloses streptococcus and a dairy cow mastitis vaccine obtained by inactivating the streptococcus. The active components of the dairy cow mastitis vaccine are an inactivated strain SAWR-6 (streptococcus agalactiae-6), an inactivated strain SDTR-9 (streptococcus dysgalactiae-9) and an inactivated strain SURF-5 (streptococcus uberis-5). The invention also provides a dairy cow mastitis vaccine, of which the active components are inactivated strains and capsular polysaccharides, wherein the inactivated strains are an inactivated strain SAWR-6, an inactivated strain SDTR-9 and an inactivated strain SURF-5; the capsular polysaccharides are strain SAWR-6 capsular polysaccharide, strain SDTR-9 capsular polysaccharide and strain SURF-5 capsular polysaccharide. The vaccine disclosed by the invention has the advantages of high efficiency, universality, safety, stability, various preparations and the like, a powerful guarantee is provided to safe, effective and comprehensive and effective prevention of streptococcus infected dairy cow mastitis, and the vaccine is a new milestone for the development of dairy cow mastitis vaccine.